Pfizer Highlights Promising Phase 2 Results for Monthly Obesity Drug Berobenatide

Pfizer has shared new data from several Phase 2b clinical studies of berobenatide (PF-07976016), an investigational obesity treatment that could become the first monthly GLP-1 receptor agonist peptide therapy.

The results were presented during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA). The studies focused on evaluating different doses and dosing schedules to identify the best approach for future Phase 3 development.

The findings suggest that berobenatide may offer meaningful weight loss, good tolerability, and the convenience of monthly dosing, which could make long-term treatment easier for many patients.

What Makes Berobenatide Different?

Most currently available GLP-1 therapies require weekly injections. Berobenatide is being developed as a monthly treatment option while still delivering competitive weight-loss results.

The drug is designed as a GLP-1 receptor agonist peptide and is being studied in people living with obesity or overweight, both with and without type 2 diabetes.

According to Pfizer, berobenatide is delivered through a small 0.5 mL injection, which may offer convenience and support large-scale use if approved.

Strong Weight Loss Results Continue Beyond 32 Weeks

One of the most notable findings came from the exploratory extension phase of the VESPER-1 study.

Participants who transitioned from placebo to weekly berobenatide 2.4 mg achieved a non-placebo-adjusted weight loss of 15.9% after 32 weeks of treatment. Researchers also reported that weight loss continued throughout the study period, with no signs of reaching a plateau.

These results are encouraging because they suggest that patients may continue losing weight over an extended period rather than seeing progress slow down after several months.

Positive Results in Patients With Type 2 Diabetes

The VESPER-2 study evaluated berobenatide in adults living with obesity or overweight who also had type 2 diabetes.

Researchers observed dose-dependent improvements in both body weight and blood sugar control.

Patients receiving the 1.6 mg weekly dose achieved a 2.2% reduction in HbA1c after 28 weeks of treatment. In comparison, the placebo group showed only a 0.2% reduction.

The findings suggest that berobenatide could potentially help address two major health challenges at the same time: obesity and diabetes management.

Monthly Dosing Could Improve Long-Term Treatment Adherence

Weight management often requires long-term treatment, and staying on therapy can be difficult for many patients.

According to Dr. John B. Buse of the University of North Carolina School of Medicine, the convenience of monthly dosing may become an important advantage for patients who struggle with long-term treatment adherence.

The Phase 2b studies showed that patients maintained meaningful weight loss even after transitioning from weekly treatment to monthly maintenance dosing.

If future studies confirm these results, berobenatide could offer a practical treatment option that fits more easily into patients' lives.

Safety and Tolerability Remain Encouraging

Another important finding from the studies was the drug's tolerability profile.

Despite relatively rapid dose escalation, researchers reported low rates of gastrointestinal side effects and treatment discontinuations. No dose step-downs were allowed during the studies, making the favorable safety profile particularly noteworthy.

The majority of GLP-1 therapies are commonly associated with gastrointestinal side effects, making tolerability an important factor when evaluating new treatment options.

Understanding the VESPER Clinical Program

Pfizer's VESPER program is a large clinical development initiative designed to evaluate berobenatide across different patient populations and treatment approaches.

The completed and ongoing Phase 2 studies have focused on weekly and monthly dosing in patients with obesity, overweight, and type 2 diabetes.

The program is now advancing into Phase 3 development.

Current Phase 3 studies are evaluating both weekly and monthly dosing schedules in broader patient populations. Additional studies are also planned to examine obesity-related conditions such as obstructive sleep apnea and knee osteoarthritis.

Pfizer Expands Its Obesity Pipeline

Pfizer has ambitious plans for its obesity research program.

The company expects to launch more than 20 obesity-related clinical trials in 2026. This includes ten ongoing and planned Phase 3 studies involving berobenatide.

In addition to studying the drug as a standalone therapy, Pfizer is also exploring combinations with other metabolic treatments, including ultra-long-acting amylin analogs.

The company's broader strategy is to build a portfolio of treatments that can address the diverse needs of people living with obesity and related health conditions.

Why New Obesity Treatments Are Needed

Obesity continues to be one of the fastest-growing global health challenges.

In 2015, approximately 1.9 billion people worldwide were classified as overweight or living with obesity. That number is expected to exceed 2.9 billion by 2030.

Obesity is linked to more than 200 health conditions, including type 2 diabetes, cardiovascular disease, sleep disorders, and joint problems. While current therapies have improved treatment options, many patients still face challenges related to efficacy, side effects, affordability, and long-term adherence.

This is why pharmaceutical companies continue to invest heavily in developing new treatment approaches.

Looking Ahead

The latest Phase 2b results strengthen Pfizer's confidence in berobenatide as a potential new option for chronic weight management.

The combination of significant weight loss, improved blood sugar control, favorable tolerability, and the possibility of once-monthly dosing could help differentiate the treatment in an increasingly competitive obesity market.

With multiple Phase 3 studies already underway and additional research planned, Pfizer is positioning berobenatide as a potential next-generation therapy that could offer patients a more convenient and sustainable approach to managing obesity and related conditions.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!